This page shows the latest CD3 news and features for those working in and with pharma, biotech and healthcare.
Sanofi and Regeneron are also working on bispecific antibody immunotherapies, including two lead candidate targeting BCMA/CD3 and MUC/CD3, respectively.
The antibody targets BCMA, a protein that is typically over-expressed on multiple myeloma cells, by binding to it and the CD3 receptor on T-cells, bringing them together and activating ... CD3 targeting bispecific antibody.
Teplizumab works by binding to the pro-inflammatory T cell co-receptor CD3, which in turn prevents them from activating the T cells that attack and kill the pancreas’ beta cells.
Teplizumab is a mouse derived anti-CD3 mAb, and is administered intravenously. ... Now Tiziana is looking to rival Provention with the development of its own anti-CD3 mAB foralumab, which it says is the only entirely human anti-CD3 mAb.
Roche is also looking at combining Polivy with its CD20/CD3 bispecific antibody mosunetuzumab in DLBCL and follicular lymphoma, and moving the ADC into earlier lines of therapy.
Teplizumab works by binding to the pro-inflammatory T cell co-receptor CD3, which in turn prevents them from activating the T cells that attack and kill the pancreas’ beta cells.
More from news
Approximately 2 fully matching, plus 23 partially matching documents found.
Its fully human engineered CD3 antibody Foralumab has reached phase II with potential for a wide range of autoimmune and inflammatory diseases such as non-alcoholic steatohepatitis (NASH), primary biliary cholangitis,
Both antibodies have a cytotoxic T-cell binding domain (CD3), which activates T-cells at the site of the tumour for killing of malignant cells, and a specific tumour antigen binding
platform. The antibody targets both CD19 and CD3 and is being developed for the treatment of B-cell malignancies.
187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).
CD123 and CD3.
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Shailubhai takes the helm as Tiziana focuses on developing an orally administered, anti-CD3 mAb (foalumab) drug candidate to manage non-alcoholic steatohepatitis (NASH) - a liver disease that has no treatment
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....